12 结果
FIELD OF THE INVENTION
The present invention concerns gyrase inhibitor-protein conjugates and in particular gyrase inhibitor-albumin conjugates, pharmaceutical preparations comprising gyrase inhibitor-protein conjugates in particular for the treatment and/or prophylaxis of inflammatory processes
RELATED APPLICATIONS
This application is a national stage application (under 35 U.S.C. .sctn.371) of PCT/DE2007/001427, filed Aug. 10, 2007, which claims benefit of German application 102006037613.7, filed Aug. 10, 2006 and German application 102006048249.2, filed Oct. 12, 2006.
DESCRIPTION
The
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to drug formulation of hydrophobic photosensitizer. In particular, the invention relates to nanoparticle formulations containing hydrophobic photosensitizers, to their method of preparation and to their use in
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease.
BACKGROUND OF THE INVENTION
Neutrophil adhesion to activated endothelial cells and trans-endothelial migration of these cells are essential
BACKGROUND OF THE INVENTION
The inflammatory response governs a wide range of illness from injury to infections and allergies. Initiating inflammation involves activating immune cells that trigger the phospholipase A.sub.2 (PLA.sub.2)-involved inflammatory processes. PLA.sub.2 enzymes are a diverse
BACKGROUND OF THE PRESENT INVENTION
1. Field of Invention
The subject invention relates generally to a series of natural pharmaceutical preparations which can treat hypoproteinemia for increasing albumin. The preparations could be used to treat hypoproteinemia caused by hepatitis virus, human
The sequence listing in the file named "43272ol1805.txt" having a size of 341,671 bytes that was created Apr. 3, 2014 is hereby incorporated by reference in its entirety.
BACKGROUND
1. Field of the Art
This invention is an extension of Applicants' prior invention disclosed in the above-referenced
BACKGROUND
1. Technical Field
The invention is in the fields of drug therapy; more specifically, the invention encompasses a protein for immunosuppression.
2. The Prior Art
The central nervous system (CNS) actively maintains immune privilege (Carson and Sutcliffe, 1999; Fabry et al., 1994), in part
FIELD OF THE INVENTION
The present disclosure relates to the treatment of allergic dermatitis, and in particular to allergic dermatitis resulting from contact with naturally-occurring hydrophobic toxins such as urushiol and isosolenopsin A.
BACKGROUND OF THE INVENTION
Allergic dermatitis can be
RELATIONSHIP TO THE PRIOR ART
The concept of using conjugates of leukotrienes in a radioimmunoassay was described, by L. Levine, R. A. Morgan, R. A. Lewis, K. F. Austin, D. A. Clark, A. Marfat, and E. J. Corey, Proceeding of the National Academy of Sciences, U.S.A., Vol. 78, No. 12 7692 (1981) This
RELATIONSHIP TO THE PRIOR ART
The concept of using conjugates of leukotrienes in a radioimmunoassay was described, by L. Levine, R. A. Morgan, R. A. Lewis, K. F. Austin, D. A. Clark, A. Marfat, and E. J. Corey, Proceeding of the National Academy of Sciences, U.S.A., Vol. 78, No. 12 7692 (1981). This
FIELD OF THE INVENTION
The present invention relates to anti-Tumor Necrosis Factor polypeptides comprising one or more antibody single variable domains, or antigen-binding fragments thereof, in particular, dimers comprising two light chain variable domains that have high solubility. It also relates